Zepzelca (lurbinectedin)

Numéro de dossier de l’APP: 22128

État des négociations:

Under consideration for negotiation

Indication(s):

For the treatment of adult patients with Stage III or metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-containing therapy

Promoteur/fabricant:

Jazz Pharmaceuticals Canada Inc.

Numéro de projet de l’ACMTS:

PC0281

Lettre-contrat de l’APP:

Not Applicable

Conclusion du processus de négociation:

Not Applicable